Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Trial of IMPT-514 in SLE, AAV, and IIM
NCT06462144Phase 1Terminated
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jun 2024
- Primary completion
- Oct 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMPT-514 in systemic lupus erythematosus (SLE), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and idiopathic inflammatory myopathy (IIM), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Incidence of dose limiting toxicities (DLTs), serious adverse events (SAE) and treatment-emergent adverse events (TEAEs) at 28 days. Started Jun 2024; status: terminated.
02
Drugs
IMPT-514
03
Conditions
systemic lupus erythematosus (SLE)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT06462144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462144.